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A COMPARISON OF EFFICACY OF FLUTICASONE WITH BUDESONIDE 
AND BECLOMETHASONE IN 1:1 DOSE RATIO IN THE TREATMENT OF 
BRONCHIAL ASTHMA
Pankiewicz O, Nadzieja-Koziol A, Kwaskowski A, Jaros P, Jagodzinska K, Lach K, 
Jarczewska D, Rys P, Wladysiuk M, Plisko R
HTA Consulting, Krakow, Poland
OBJECTIVES: This study compared efﬁcacy of ﬂuticasone (FL) with budesonide 
(BUD) and beclomethasone (BDP) in 1:1 dose ratio in the treatment of bronchial 
asthma. METHODS: Comparison was based on randomized controlled trials (RCTs) 
identiﬁed by means of systematic review, carried out according to the Cochrane Col-
laboration guidelines and Agency for Technology Assessment in Poland. The most 
important medical databases (EMBASE, MEDLINE and CENTRAL) were searched. 
Two reviewers independently selected trials, assessed their quality and extracted 
data. Head-to-head comparisons were performed. RESULTS: The systematic search 
retrieved 11 and 10 RCTs for comparison FL vs. BUD and 10 for FL vs. BDP, respec-
tively. Incidence of asthma exacerbations in FL and BUD was comparable. Signiﬁcant 
improvement in favor of FL over BUD were found in respect to Forced Expiratory 
Volume in 1 second—FEV1 (% predicted) (WMD  2.84 [0.80; 4.89]), morning (Peak 
Expiratory Flow PEF(% predicted) (WMD  3.00 [1.59; 4.41]) and proportion of 
symptoms-free days (MD  8.7; p  0.02), while Asthma Symptoms Score (ASS) didn’t 
differ between groups (MD  0.06 [0.18; 0.06]). FL in comparison with BDP was 
associated with lower risk of asthma exacerbations (RR  0.74 [0.57; 0.96]), improve-
ment in FEV1 (WMD  0.07 liter [0.01; 0.13]) and in morning PEF (% predicted) 
(WMD  1.57 [0,09; 3.06]). Moreover, efﬁcacy analysis revealed higher proportion 
of symptoms-free nights (WMD  8.30 [1.95; 14.65]) and greater reduction in ASS 
(MD  0.21 [0.37; 0.05]) in FL group. FL increased the risk of pharyngitis over 
BUD (RR  1.66 [1.01; 2.73]) and the risk of hoarseness in comparison with BDP 
(RR  2.21 [1.06; 4.60]), No other differences in safety outcomes were noted for both 
comparisons. CONCLUSIONS: Fluticasone in comparison with budesonide and 
beclomethasone in dose ratio 1:1 provides improvement in spirometric parameters and 
in comparison with beclomethasone but not budesonide reduces the risk of asthma 
exacerbations. Safety proﬁle of ﬂuticasone seems to be slightly worse than budesonide 
and beclomethasone.
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OBJECTIVES: The main objective of this study is to evaluate efﬁcacy and safety of 
ﬂuticasone in comparison with budesonide in patients with chronic obstructive pul-
monary disease (COPD). METHODS: Comparison was based on randomized con-
trolled trials (RCTs) identiﬁed by means of systematic review, carried out according 
to the Cochrane Collaboration guidelines and Agency for Technology Assessment in 
Poland. The most important medical databases (EMBASE, MEDLINE and CENTRAL) 
were searched. Two reviewers independently selected trials, assessed their quality and 
extracted data. Since no head-to-head comparisons between ﬂuticasone and budesonide 
were found indirect comparison using placebo (PLC) as reference group was per-
formed. RESULTS: The systematic search retrieved 34 RCTs which were included in 
the analysis (21 studies for FL compared with PLC and 13 for BUD vs. PLC. Indirect 
comparison showed that ﬂuticasone (FL) is statistically signiﬁcantly better than 
budesonide (BUD) in respect to Forced Expiratory Voume in 1 second (FEV1) before 
use of bronchodilator (WMD  0.05 liter [0.01; 0.09]) and after use of bronchodilator 
(WMD  0.06 liter [0.02; 0.10]), but those drugs didn’t differ in respect to FEV1 
expressed as percentage of predicted value. Moreover, morning Peak Expiratory Flow 
(PEF) was signiﬁcantly better in favor of FL (WMD  6.08 L/min [1.44; 10.72]). There 
were no statistically signiﬁcant differences between FL and BUD in risk of death (RR 
 1.24 [0.69; 2.22]), COPD exacerbations (RR  1.11 [0.85; 1.45]) and quality of life 
measured with St George’s Respiratory Questionnaire (WMD  1.12 [1.51; 3.75]). 
Risk of serious adverse events, candidosis, pneumonia and risk of withdrawals due to 
adverse events were similar in both groups. CONCLUSIONS: Treatment with ﬂuti-
casone in comparison with budesonide is associated with better improvement in spi-
rometric parameters. Fluticasone and budesonide have acceptable safety proﬁles.
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OBJECTIVES: Describe patient with Chronic Obstructive Pulmonary Disease (COPD)        
primary care in an area of Campania, a region in the southwest of Italy. METHODS: 
A retrospective naturalistic longitudinal study was conducted using information from 
general practice database with 109 general practitioner (GP) clinical records whit a 
list of 151,884 subjects registered at the end of December 2008. The database contains 
patient demographic details, medical records (e.g. diagnoses, test, etc.), drug history 
and prevention information. Case of COPD were identiﬁed on the basis of the ICD-9 
code (491, 496). All drugs prescribed were indentiﬁed according to the R03 therapeu-
tic pharmacological subgroup (drugs for obstructive airway disease) of the Anatomi-
cal-Therapeutic-Chemical-Classiﬁcation. RESULTS: A total of 4856 (3.2%) patients      
suffering from COPD were observed. Between 2006 and 2008, 32.5% of patient had 
at least one spirometry, 10.8% one hemogasanalysis and 9.3% both. In the same 
period, 45.6% had at least one inﬂuenza vaccination, 9.5% one pneumococci vaccina-
tion while 25.5% of COPD patients did not received any drug prescription for their 
disease. A total of 57.7% of COPD patients received at least one drug for their disease 
(R03), 24% had a mono-therapy and 76 % a poly-therapy. The most used drugs cat-
egory in monotherapy were Inhaled corticosteroids (41.4%), B-agonists (24.6%), 
xanthine derivatives (19.2%), anticholinergics (14.0%). Among the poly-therapy 
cohort, there was an high variety of drug categories combination, in particular the 
most frequent were the pre-constituted formulation itself (19.4%). CONCLUSIONS: 
This study shows the high variability in the management of COPD in primary care, 
which does not seem to be always consistent to published guidelines.
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OBJECTIVES: To determine persistence rates and treatment patterns of the following 
long-acting drugs used as inhaled maintenance therapies for COPD: long-acting mus-
carinic antagonists (LAMA), long-acting B2-agonists (LABA) and ﬁxed dose combina-
tions (FDC) of inhaled corticosteroids (ICS) and LABA. METHODS: From the 
PHARMO-database, all probable COPD patients were identiﬁed by new respiratory 
drug use (excluding ICS monotherapy) at age q55 years. New users of LAMA, LABA 
and FDC in the period 2002–2006 were included in the study. Persistence with the 
initial as well as any long-acting drug was determined up to three years after start and 
deﬁned as time between start and stop of initial/any therapy, allowing a gap of a60 
days between reﬁlls. For patients who failed to persist with initial therapy for one 
year, the ﬁrst change in therapy was determined. RESULTS: The study included 4448 
LAMA, 2019 LABA and 8341 FDC users. Persistence rates at 1, 2, and 3 years were 
26%, 14%, 8% for LAMA, 23%, 10%, 6% for LABA and 27%, 14%, 8% for FDC. 
Of patients who did not persist with LABA alone for one year, 9% added therapy 
(mostly LAMA) and 31% switched therapy (mostly to FDC). Of patients not persisting 
with LAMA alone, 17% added and 12% switched therapy (both mostly relating to 
FDC). In patients not persisting with FDC, add-on and switch occurred with equal 
frequency (12%) and was mostly LAMA. Persistence rates with any long-acting drug 
at 1, 2 and 3 years were 37%, 23% and 17% respectively. CONCLUSIONS: Persis-
tence with long-acting inhaled drugs in patients with COPD is low, with a substantial 
proportion of patients changing therapy. This indicates that current treatments are 
not adequate.
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OBJECTIVES: It is hypothesised that cough and/or sputum symptoms have a negative 
impact on disease burden in chronic obstructive pulmonary disease (COPD). This 
study assesses the impact of these symptoms in predicting the annual frequency of 
exacerbations in 1887 COPD patients. METHODS: Data were drawn from the 
Adelphi Respiratory Disease Speciﬁc Programme conducted in France, Germany, Italy, 
Spain, the UK and the USA in 2008. Information collected included physicians’ percep-
tions of symptom severity and frequency of exacerbations in the previous 12 months. 
GLM regressions (using Gamma distributions with log link functions) were used to 
assess the impact of various factors on exacerbation frequency. Variables investigated 
included age, gender, body mass index, breathlessness, smoking status, co-morbidities 
(heart-related and anxiety/depression), compliance, most recent forced expiratory 
volume in 1 second (FEV1, if available) and country of origin. Final models derived 
included statistically signiﬁcant variables only (p  0.05). RESULTS: Cough and/or 
sputum symptoms were associated with a signiﬁcantly higher frequency of exacerba-
tions (14% higher among patients with mild cough/sputum compared with those 
without, 18% higher among patients with moderate cough/sputum compared with 
mild, and 28% higher among patients with severe cough/sputum compared with 
moderate). A signiﬁcantly higher frequency was also observed for exacerbations 
managed in the primary care setting (28%, 24% and 34% higher, respectively). 
Among 690 patients receiving secondary care, exacerbation frequency was 161% 
higher for patients with cough and/or sputum symptoms. In addition, exacerbation 
frequency was 173% higher among secondary care patients reported as poorly or 
non-compliant with their current medication (all p  0.05). FEV1 was only a signiﬁcant 
predictor for exacerbations managed in secondary care. CONCLUSIONS: Presence 
and severity of cough and/or sputum in COPD symptoms has a marked association 
with increased frequency of exacerbations, even when considering FEV1. These results 
indicate unmet therapeutic needs in this population.
